Here’s the latest, from accessible sources up to now.
UK/NHS updates: NICE fast-tracked Alyftrek (vanzacaftor–tezacaftor–deutivacaftor) for people aged 6+ with at least one F508del CFTR mutation. This triple therapy is intended to broaden access to CFTR modulators and is positioned as comparable in effectiveness and cost to Kaftrio under a rapid NHS agreement. This marks another step in expanding CFTR modulator options for many people with CF in England [source: NICE news coverage, 2025].
CFTR modulators landscape (context): Over the past years, modulators that target CFTR defects have significantly changed CF care by addressing the underlying cause, not just symptoms, with combinations designed for patients with common mutations like F508del. Ongoing regulatory and payer decisions continue to shape who can access these therapies in different regions [general CFTR modulator context; sources referencing NICE/NHS discussions].
What this means for you in Warsaw, Poland, or elsewhere in Europe
One quick example to illustrate the trend
Would you like a country-specific update (Poland/Polish CF care) or a brief explainer of how CFTR modulators work and what “triple therapy” means in practice? I can pull the most recent country-level guidance if you specify what you’d like to know.
Citations:
CLEVELAND - Results of the pivotal Phase 3 clinical trial published in the Nov. 3, 2011 New England Journal of Medicine, find that the oral medicatio...
case.eduCystic fibrosis is a life-threatening disease that is caused by mutations in CFTR, a gene which encodes an ion channel that supports proper function of sever...
www.frontiersin.orgHow are a football match, a plug socket and a birthday cake linked to CFTR, the gene that causes cystic fibrosis? Find out by reading our ‘Research blast’ article celebrating 30 years since the gene was discovered.
www.cysticfibrosis.org.ukA Potential Breakthrough Treatment for Cystic Fibrosis Enters Clinical Trial Led by CI MED and U of Iowa Researchers
medicine.illinois.eduDecades of clinical trials have drastically improved both life expectancy and quality of life for those with cystic fibrosis, a testament to the pivotal role of clinical trials in advancing medical research and treatment
hub.jhu.eduThere's been advancement on cystic fibrosis, but there are still those living with the disease who get no relief from current treatments. Gene editing may help.
www.nhlbi.nih.govDriven by personal loss, a graduate student and his mentors unveil the mysteries of CFTR mutations, seeking to unlock new treatments for cystic fibrosis patients who currently resist available drug…
medschool.vanderbilt.eduNew cystic fibrosis drug fast-tracked for NHS use .
www.nice.org.ukProfessor Tzyh-Chang Hwang Deciphers Pathogenic Protein Structure, Advancing Drug Development for Cystic Fibrosis and Diarrheal Diseases
www.nycu.edu.twa collaboration with the CF Foundation (CFF). This CF research program would work to find medications, called modulators, to correct defective CFTR protein. Since the start of this collaboration, Vertex has developed Kalydeko® (ivacaftor), Orkambi® (lumacaftor/ivacaftor) and … paved the way for other CFTR modulators that may benefit many more patients. In 2015, lumacaftor/ivacaftor (Orkambi) combination therapy was approved by the FDA for patients with two F508del mutations (the most common CF...
www.med.umich.edu